Información del artículo
Artículo
Opciones para acceder a los textos completos de la publicación Hipertensión y Riesgo Vascular
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
R. Cervera, M.A. Khamashta, J. Font, G.D. Sebastiani, A. Gil, P. Lavilla, et al.
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients.
Medicine (Baltimore)., 82 (2003), pp. 299-308
[2]
M. Giannelou, C.P. Mavragani.
Cardiovascular disease in systemic lupus erythematosus: A comprehensive update.
J Autoimmun., 82 (2017), pp. 1-12
[3]
M.L. Hermansen, J. Lindhardsen, C. Torp-Pedersen, M. Faurschou, S. Jacobsen.
The risk of cardiovascular morbidity and cardiovascular mortality in systemic lupus erythematosus and lupus nephritis: A Danish nationwide population-based cohort study.
Rheumatology (Oxford)., 56 (2017), pp. 709-715
[4]
S. Manzi, E.N. Meilahn, J.E. Rairie, C.G. Conte, T.A. Medsger Jr., L. Jansen-McWilliams, et al.
Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study.
Am J Epidemiol., 145 (1997), pp. 408-415
[5]
Y. Asanuma, A. Oeser, A.K. Shintani, E. Turner, N. Olsen, S. Fazio, et al.
Premature coronary-artery atherosclerosis in systemic lupus erythematosus.
N Engl J Med., 349 (2003), pp. 2407-2415
[6]
M. McMahon, B.H. Hahn, B.J. Skaggs.
Systemic lupus erythematosus and cardiovascular disease: Prediction and potential for therapeutic intervention.
Expert Rev Clin Immunol., 7 (2011), pp. 227-241
[7]
J.M. Esdaile, M. Abrahamowicz, T. Grodzicky, Y. Li, C. Panaritis, R. du Berger.
Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.
Arthritis Rheum., 44 (2001), pp. 2331-2337
[8]
G.C. Wu, H.R. Liu, R.X. Leng, X.P. Li, X.M. Li, H.F. Pan, et al.
Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis.
Autoimmun Rev., 15 (2016), pp. 22-37
[9]
E.B. Taylor, M.J. Ryan.
Understanding mechanisms of hypertension in systemic lupus erythematosus.
Ther Adv Cardiovasc Dis., (2016),
pii: 1753944716637807. [Epub ahead of print]
[10]
D. Bonciani, E. Antiga, V. Bonciolini, A. Verdelli, E. Del Bianco, W. Volpi, et al.
Homocysteine serum levels are increased and correlate with disease severity in patients with lupus erythematosus.
Clin Exp Rheumatol., 34 (2016), pp. 76-81
[11]
M.J. Roman, B.A. Shanker, A. Davis, M.D. Lockshin, L. Sammaritano, R. Simantov, et al.
Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus.
N Engl J Med., 349 (2003), pp. 2399-2406
[12]
L.B. Lewandowski, M.J. Kaplan.
Update on cardiovascular disease in lupus.
Curr Opin Rheumatol., 28 (2016), pp. 468-476
[13]
D.K. Wells, M.M. Ward.
Nephritis and the risk of acute myocardial infarction in patients with systemic lupus erythematosus.
Clin Exp Rheumatol., 28 (2010), pp. 223-229
[14]
M. Dobre, T.W. Meyer, T.H. Hostetter.
Searching for uremic toxins.
Clin J Am Soc Nephrol., 8 (2013), pp. 322-327
[15]
J.A. Todolí-Parra, Y. Tung-Chen, L. Micó, J. Gutiérrez, J. Hernández-Jaras, J.L. Ruiz-Cerda.
Lupus nephritis with preserved kidney function associated with poorer cardiovascular risk control: A call for more awareness.
Hipertens Riesgo Vasc., (2018), pp. 35
